Zakażenia u ciężarnych – czy TORCH nadal jest dominujący?

Infections in pregnancy – is TORCH still dominant?

Anna Boroń-Kaczmarska

Katedra i Klinika Chorób Zakaźnych Krakowskiej Akademii im. Andrzeja Frycza-Modrzewskiego

Anna Boroń-Kaczmarska
Katedra i Klinika Chorób Zakaźnych
Krakowska Akademia im. Andrzeja Frycza-Modrzewskiego
ul. Herlinga-Grudzińskiego 1, 30-705 Kraków

Wpłynęło: 20.05.2019
Zaakceptowano: 19.06.2019
Opublikowano on-line: 10.07.2019

Cytowanie / Citation

Boroń-Kaczmarska A. Zakażenia u ciężarnych – czy TORCH nadal jest dominujący.
Zakażenia XXI wieku 2019;2(3):107–113
doi: 10.31350/zakazenia/2019/3/Z2019024

Wersja elektroniczna / Article ePDF

Streszczenie:
Zakażenie w ciąży to wysoce skomplikowane zagadnienie ze względu na to, że infekcje przebiegające łagodnie u dorosłych mogą być transmitowane do płodu. Konsekwencje takiego zjawiska to zagrożenie dalszego rozwoju, a nawet życia dziecka w okresie jego wewnątrzmacicznego życia. Przedstawiona praca poglądowa dotyczy krótko- i długoczasowych powikłań w wybranych zakażeniach u kobiet w ciąży. Akronim TORCH jest dyskutowany jako zbyt wąskie określenie zakażeń teratogennych.

Słowa kluczowe: ciąża, układ immunologiczny, wybrane zakażenia w ciąży

Abstract:
Infectious disease during pregnancy is a complicated issue because many common infections that may cause mild to moderate symptoms in an adult can be transmitted to the fetus. These infections potentially result in moderate to severe complications for the developing fetus which may have long-term sequelae. This review will explore the possible short- and long-term perinatal outcomes of selected common infections in pregnancy. An acronym TORCH has been dissccussed as a too narrow definition of teratogenic infections.

Key words: pregnancy, immune system, selected infections in pregnancy

  1. Adams Waldorf KM, McAdams RM. Influence of infection during pregnancy on fetal development. Reproduction 2013;146(5):R151–R162. doi: 1530/REP-13-0232
  2. Schwartz MD. The origins and emergence of Zika virus, the newest TORCH infection. Arch Pathol Lab Med 2017;141(1):18–25. doi:  5858/arpa.2016-0429-ED
  3. Vermillion MS, Klein SL. Pregnancy and infection: using disease pathogenesis to inform vaccine strategy. NPJ Vaccine 2018;3:6. doi:  1038/s41541-017-0042-4
  4. Neu N, Duchon J, Zachariah P. TORCH infections. Clin Perinatol 2015;42(1):77–103. doi:  1016/j.clp.2014.11.001
  5. Bale JF Jr, Murph JR. Congenital infections and the nervous system. Pediatr Clin North Am 1992;39(4):669–690. doi:  1016/S0031-3955(16)38370-5
  6. Villines Z. Common infections during pregnancy. Medical News Today (https://www.medicalnewstoday.com/articles/322210.php)
  7. Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reproductive Immunol 2010;63(6):425–433. doi:  1111/j.1600-0897.2010.00836.x
  8. Aghaeepour N, Ganio EA, Mcilwain D i wsp. An immune clock of human pregnancy. Science Immunol 2017;2(15)pii:eaan2946. doi:  1126/sciimmunol.aan2946
  9. Stagno S, Pass RF, Cloud G i wsp. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 1986;256(14):1904–1908. doi:  1001/jama.1986.03380140074025
  10. Lanzieri TM, Dollard SC, Bialek SR i wsp. Systematic review of the birth prevalence of congenital cytomegalovirus infection in developing countries. Int J Infect Dis 2014;22:44–48. doi:  1016/j.ijid.2013.12.010
  11. Picone O, Vauloup-Fellous C, Cordier AG i wsp. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 2013;33(8):751–758. doi:  1002/pd.4118 
  12. Gindes L, Teperberg-Oikawa M, Sherman D i wsp. Congenital cytomegalovirus infection following primary maternal infection in the third trimester. BJOG 2008;115(7):830–835. doi:  1111/j.1471–0528.2007.01651.x
  13. Lazzarotto T, Guerra B, Lanari M i wsp. New advances in the diagnosis of congenital cytomegalovirus infection. J Clin Virol 2008;41(3):192–197. doi:  1016/j.jcv.2007.10.015
  14. Leruez-Ville M, Sellier Y, Salomon LJ i wsp. Prediction of fetal infection in cases with cytomegalovirus immunoglobulin M in the first trimester of pregnancy: a retrospective cohort. Clin Infect Dis 2013;56(10):1428–1435. doi:  1093/cid/cit059
  15. Pass RF, Arav-Boger R. Maternal and fetal cytomegalovirus infection: diagnosis, management, and prevention. F1000Res 2018;7:255. doi:  12688/f1000research.12517.1
  16. Rawlinson WD, Boppana SB, Fowler KB i wsp. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 2017;17(6):e177–e188. doi:  1016/S1473–3099(17)30143–3
  17. Lazear HM, Diamond MS. Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J Virol 2016;90(10):4864–4875. doi:  1128/JVI.00252-16
  18. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill 2014;19(13)pii:20751.
  19. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med 2016;374(20):1981–1987. doi:  1056/NEJMsr1604338
  20. Melo AS, Aguiar RS, Amorim MM i wsp. Congenital zika virus infection: beyond neonatal microcephaly. JAMA Neurol 2016;73(12):1407–1416. doi:  1001/jamaneurol.2016.3720
  21. Paixao ES, Leong WY, Rodrigues LC, Wilder-Smith A. Asymptomatic prenatal Zika virus infection and congenital Zika syndrome. Open Forum Infect Dis 2018;5(4):ofy073. doi:  1093/ofid/ofy073
  22. Halai UA, Nielsen-Saines K, Moreira ML i wsp. Maternal Zika virus disease severity, virus load, prior dengue antibodies, and their relationship to birth outcomes. Clin Infect Dis 2017;65(6):877–883. doi:  1093/cid/cix472
  23. Pomorska D, Kuchar E. Zakażenie wirusem zika – nowe zagrożenie epidemiczne. Pediatr Med Rodz 2016;12(2):150–156. doi:  15557/PiMR.2016.0014
  24. https://www.who.int/csr/resources/publications/zika/laboratory-testing/en/2016).
  25. Balayan MS. Epidemiology of hepatitis E virus infection. J Viral Hepat 1997;4(3):155–165.
  26. Khurro MS, Khurro MS, Khurro NS. Hepatitis E: discovery, global impact, control and cure. World J Gastroenterol 2016;22(31):7030–7045. doi:  3748/wjg.v22.i31.7030
  27. Khuroo MS, Kamil S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat 2003;10(1):61–69
  28. Khaskheli MN, Baloch S, Sheeba A, Baloch S. Acute hepatitis E viral infection in pregnancy and maternal morbidity. J Coll Physicians Surg Pak 2015;25(10):734–737. doi:  2015/JCPSP.734737.
  29. Sayed I, Vercouter AS, Abdelwahab S, Vercautresn K, Meuleman P. Is hepatitis E virus an emerging problem in industrialized countries? Hepatology 2015;62(6):1883–1892. doi:  1002/hep.27990.
  30. Chaudhry S, Verma N, Koren D. Hepatitis E infection during pregnancy. Can Fam Physician 2015;61(7):607–608.
  31. Perez-Garcia MT, Suay-Garcia B, Mateos-Lindemann ML. Hepatitis E and pregnancy: current state. Red Med Virol 2017;27:e1929. doi:  1002/rmv.1929

 

Konflikt interesów: nie zgłoszono.
Potential conflicts of interest: no conflicts.

MAVIPURO POLSKA Sp. z o.o.
ul. Wyspowa 2/13
03-687 Warszawa
Tel.: +48 22 110 03 81
Fax:   +48 22 378 28 51
e-mail: kontakt@mavipuro.pl

 

POLITYKA PRYWATNOŚCI

 

 

PIERWSZE MAZOWIECKIE SPOTKANIE MIKROBIOLOGÓW I EPIDEMIOLOGÓW


» PROGRAM


» REJESTRACJA